Therapeutic prospects of mycophenolate mofetil for the treatment of neurodermatitis

Abstract

Mycophenolate mofetil (MMF), an inhibitor of inosine 5′-monophosphate dehydrogenase, serves to suppress the immune response against alloantigens by hindering purine nucleotide synthesis in immune cells. At present, MMF is US FDA approved for the prevention of allogeneic renal transplant rejection. In this report, the authors demonstrate, to their knowledge, the first case of successful treatment of neurodermatitis complicated by lichen simplex chronicus and prurigo nodularis with MMF.